Vilitra is a prescription medication containing Vardenafil, a potent PDE5 inhibitor clinically proven to restore erectile function in men. Developed for reliable and predictable results, it facilitates increased blood flow to the penile tissues upon sexual stimulation. This medication is designed for adult men experiencing erectile dysfunction (ED) and is available in multiple strengths to allow for personalized treatment plans under medical supervision. Its formulation ensures rapid onset and sustained duration, making it a trusted choice among healthcare providers for managing this condition.

Features

• Active ingredient: Vardenafil 10mg, 20mg, 40mg
• Rapid onset of action: as fast as 25–60 minutes
• Long duration of efficacy: up to 4–5 hours
• High selectivity for PDE5 enzyme
• Film-coated tablet for ease of administration
• Manufactured under GMP-certified conditions

Benefits

• Restores the ability to achieve and maintain a firm erection suitable for sexual activity.
• Enhances confidence and reduces anxiety associated with sexual performance.
• Allows for spontaneity due to its rapid onset and predictable effects.
• Supports improved intimate relationships and overall quality of life.
• Offers flexibility with multiple dosage strengths for tailored therapy.
• Backed by extensive clinical research demonstrating efficacy and safety.

Common use

Vilitra is primarily prescribed for the treatment of erectile dysfunction (ED) in adult males. It is suitable for individuals with various underlying causes of ED, including physiological, psychological, or mixed etiology. It may also be used off-label in certain cases of pulmonary arterial hypertension under strict medical guidance, though this is less common. Patients are advised to use it only as needed, in anticipation of sexual activity.

Dosage and direction

The recommended starting dose of Vilitra is 10mg, taken approximately 25–60 minutes before anticipated sexual activity. Based on efficacy and tolerability, the dose may be increased to 20mg or decreased to 5mg. The maximum recommended frequency is once per day. It should be taken orally with or without food, though high-fat meals may delay onset. Do not crush or split the tablet. Always follow the specific instructions provided by your healthcare provider.

Precautions

• Not intended for use by women, children, or adolescents.
• Use with caution in patients with cardiovascular disease; sexual activity poses potential cardiac risk.
• Avoid consumption of grapefruit or grapefruit juice, as it may increase drug levels.
• Priapism (prolonged erection >4 hours) requires immediate medical attention to avoid permanent damage.
• Inform your physician of any history of bleeding disorders, retinal conditions, or anatomical penile deformities.
• Alcohol consumption in moderation is advised, as excessive intake may increase risk of side effects or reduce efficacy.

Contraindications

• Hypersensitivity to Vardenafil or any component of the formulation.
• Concurrent use of nitrates or nitric oxide donors in any form.
• Patients with severe hepatic impairment (Child-Pugh Class C).
• History of non-arteritic anterior ischemic optic neuropathy (NAION).
• Concomitant use with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir.
• Unstable angina, recent stroke, myocardial infarction, or life-threatening arrhythmia.

Possible side effects

Common side effects may include headache, flushing, nasal congestion, dyspepsia, and dizziness. Less frequently, patients may experience blurred vision, altered color perception, back pain, or myalgia. Serious but rare adverse effects include sudden hearing loss, priapism, or severe cardiovascular events. Most side effects are mild to moderate and transient. Report any persistent or severe symptoms to your healthcare provider.

Drug interaction

Vilitra may interact with:

• Nitrates and recreational nitrites (“poppers”), causing dangerous hypotension.
• Alpha-blockers (e.g., tamsulosin), potentially leading to symptomatic hypotension.
• CYP3A4 inhibitors (e.g., erythromycin, clarithromycin) increasing Vardenafil exposure.
• Antihypertensive agents, potentially amplifying blood pressure-lowering effects.
• Protease inhibitors used in HIV treatment.
• Other PDE5 inhibitors; concomitant use is strictly contraindicated.

Missed dose

Vilitra is taken on an as-needed basis; there is no scheduled dosing regimen. If you miss a planned dose, it may be taken later if sufficient time remains before sexual activity. Do not double the dose or take more than one tablet within 24 hours.

Overdose

In case of suspected overdose, seek immediate medical attention. Symptoms may include severe headache, hypotension, syncope, prolonged erection, or visual disturbances. Standard supportive measures should be employed; haemodialysis is not expected to significantly enhance elimination.

Storage

Store at room temperature (15–30°C) in a dry place, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis, treatment options, and personalized recommendations. Do not initiate, adjust, or discontinue medication without medical supervision.

Reviews

“After six months of use, Vilitra has consistently delivered results. As a urologist, I appreciate its reliability and patient satisfaction rates.” – Dr. A. Reynolds, MD
“Effective and well-tolerated. The 20mg dose works predictably for me with minimal side effects.” – Mark T., patient
“Switched from another ED medication—noticed faster onset and fewer instances of facial flushing. Very pleased.” – James L.
“As a cardiologist, I prescribe Vilitra cautiously but find it valuable for suitable patients. Clear contraindications must be respected.” – Dr. L. Gupta, cardiology
“Simple to use, discreet packaging. It has greatly improved my confidence and relationship.” – Robert K.